Navigation Links
New Versa HD System Tops Elekta's Comprehensive Array of Cancer Management Solutions at 2nd ESTRO Forum
Date:4/15/2013

GENEVA, April 15, 2013 /PRNewswire/ -- ESTRO Booth #3400 – Elekta will debut its Versa HD™ system at the first major exhibition since the company introduced the advanced linear accelerator globally on March 1. The 2nd ESTRO (European Society for Radiotherapy and Oncology) Forum convenes April 19-23 at the Palexpo convention center in Geneva.

Versa HD features high-precision beam shaping and tumor targeting, and the versatility to deliver high-volume conventional therapies, plus the most sophisticated linear accelerator-based treatments that require extreme targeting precision. Elekta will also highlight its newly redesigned Flexitron® remote afterloading platform for brachytherapy designed to improve safety and efficiency in the brachytherapy workflow, as well as new programs to simplify the upgrade path from competitive oncology information systems (OIS) to MOSAIQ® OIS.

"We expect great interest in Versa HD at this year's ESTRO Forum," says Ian Alexander , Elekta's Executive Vice President Region Europe, Africa, Latin America and Middle East. "Our most advanced linear accelerator was inspired by the advent of new and more sophisticated therapies that are showing great promise worldwide, combined with growing global cancer management challenges. It truly represents a unique radiotherapy solution that will impact patient health and quality of life."

"High-definition, high-speed beam shaping, combined with high dose rate delivery makes Versa HD the ideal SBRT machine," says Oscar Matzinger , M.D., radiation oncologist at Centre Hospitalier Universitaire Vaudois (Lausanne, Switzerland) and Hopital Riviera (Vevey, Switzerland). "More and more radiotherapy patients will be treated with SBRT, which now usually involves relatively long treatment times. In treating lung cancer or liver metastases, the faster we can deliver therapy the less chance for patient motion, and, in turn, the more precise therapy will be. The High Dose Rate mode of Versa HD certainly facilitates that."

Elekta will give live presentations of Versa HD at its exhibit booth (#3400) during the ESTRO Forum.

Other meeting highlights

  • Redesigned Flexitron remote afterloading platform will emphasize safety and efficiency in the brachytherapy workflow, increasing the clinician's confidence that execution of all workflow steps proceed as planned. Included in the redesign are multiple novel advances that optimize the treatment delivery process.
  • MOSAIQ OIS connectivity will also be demonstrated, highlighting simple programs to migrate from legacy Siemens LANTIS™ systems to MOSAIQ. MOSAIQ is in use at more than 3,000 sites, interfacing with delivery systems from a range of providers, including Elekta, Siemens, Varian, TomoTherapy, Accuray and Brainlab.
  • Elekta will host a lunch symposium titled "Pioneer in Cancer Care," on April 20, from 13:15-14:30, in Room C, Lower Level. Subjects include Versa HD, VMAT, Agility™ and High Dose Rate mode, and Flexitron remote afterloading platform.

Learn more at www.elekta.com/ESTRO

Versa HD is not available for sale or distribution in all markets.  

For further information, please contact:
Johan Andersson , Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: johan.andersson@elekta.com  
Time zone: CET: Central European Time

Michelle Joiner , Director, Global Public Relations and Brand Management, Elekta 
Tel: +1 770-670-2447, email: michelle.joiner@elekta.com 
Time zone: ET: Eastern Time

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives. 

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com


'/>"/>
SOURCE Elekta
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
2. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
3. Collagen Matrix Celebrates 15th Anniversary in the Medical Device Business
4. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
5. Pharmacists United for Truth and Transparency Marks One Year Anniversary of Fighting Abuses by Pharmacy Benefits Managers
6. Life Extension Nutrition Center Healthy Living Fair celebrates first-year anniversary September 7-15
7. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
8. Hitachi Aloka Medical Releases Noblus, Advanced Versatile Ultrasound with Flexible Style
9. Hamamatsu introduces the versatile ORCA-Flash4.0 V2 sCMOS camera
10. Managed Health Care Associates, Inc. (MHA) Marks Tenth Anniversary of Hosting Annual Business Summit for Long Term Care, Home Infusion, Home Medical Equipment and Specialty Pharmacies
11. PrimerLife.com, a Skolkovo Participant Company, Celebrates Anniversary of DNA Discovery with Launch of New Social Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017  IRIDEX Corporation (Nasdaq: IRIX ) ... the first quarter 2017 after the close of trading ... will host a corresponding conference call beginning at 2:30 ... interested in listening to the conference call may do ... (703) 326-3030 for international callers, using conference ID: 92158987.  ...
(Date:4/19/2017)... India , April 19, 2017 ... and Application, Forecast to 2022 report has covered and analysed ... statistics and information on market size, shares and growth factors. ... major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and Figures, ...
(Date:4/19/2017)... N.J. , April 19, 2017  Novartis ... by the National Heart, Lung, and Blood Institute ... demonstrating that 58% of patients with treatment-naïve severe ... months when treated with eltrombopag at the initiation ... . The study evaluated three sequential treatment groups, ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... April 21, 2017 , ... ... named Agency of Record (AOR) for Theravent, Inc. , the makers of ... parent company, Foundation Consumer Healthcare, is now working to expand distribution in anticipation ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Alive for ... who wish to overcome their mental health struggles. The Alive team uses advanced ... says: “Our approach in dealing with a mental health struggle is based on ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... is seeking candidates to serve on its Accreditation and Standards Committees to ... ultimate mission is improving image quality and reducing patient radiation dose,” reports ...
(Date:4/21/2017)... ... ... and Overseer at The House of Yahweh in Abilene, Texas, wrote an open letter this ... to peace plan. Yisrayl says war has never brought peace and he knows the only ... , Yisrayl says war drums are beating all over the media and the tensions ...
(Date:4/21/2017)... ... April 21, 2017 , ... A ... for older shoulder replacement patients; post-operative recovery just might be even better than ... patients presenting with osteoarthritis following surgery: 262 patients under 65 and 103 patients ...
Breaking Medicine News(10 mins):